Nephrology News and Research

RSS

Nephrology is a branch of internal medicine and pediatrics dealing with the study of the function and diseases of the kidney.

Researchers generate three-dimensional kidney structures from human stem cells

Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.

18 Nov 2013

Patients who undergo gastric bypass less likely to have risk of heart attack and stroke

New research from the Cleveland Clinic shows most patients with diabetes and obesity who undergo gastric bypass not only experience remission of their diabetes and lose significant weight, but they also reduce their risk of having a heart attack by 40 percent and their risk for suffering a stroke by 42 percent, over a 10-year time horizon.

16 Nov 2013

MGH investigators identify molecule that plays key role in the breakdown of kidney filter

One of the most devastating side effects of diabetes is kidney failure, and one of the earliest signs of kidney damage is a disruption of the organ's filtering capacity. Diabetes patients who develop kidney failure must go on dialysis, seriously limiting their quality of life and placing them at significantly increased risk of death. The incidence of kidney disease is increasing with rising rates of obesity-associated type 2 diabetes, but very little progress has been made towards protecting the kidney's filter barrier during the past 50 years.

16 Nov 2013

Satellite Healthcare, NKF partner to sponsor free Community Kidney Disease Symposium

Satellite Healthcare, one of the nation's first and leading not-for-profit providers of kidney dialysis services and a major sponsor of kidney research, is proud to announce that it has partnered with the National Kidney Foundation to sponsor NKF's free Community Kidney Disease Symposium this Saturday, November 16th in Stockton, California.

16 Nov 2013

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

OPKO Health, Inc., has completed patient recruitment in the first phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

16 Nov 2013

Gastric bypass dramatically improves multiple cardiovascular risk factors in the long term

15 Nov 2013

Small molecule compound shows significant success in controlling polyomaviruses

A team of scientists reports that a small molecule compound showed significant success in controlling the infectivity and spread of three polyomaviruses in human cell cultures. To date there has been no medicine approved to treat such viruses, which prey on transplant recipients, people with HIV, and others whose immune systems have been weakened.

15 Nov 2013

Annexin A5 protein may have therapeutic potential for treatment of sepsis

Sepsis is the leading cause of in-hospital death and there is no specific treatment for it. Now, research led by Dr. Qingping Feng of Western University (London, Canada) suggests a protein called recombinant human annexin A5 may have therapeutic potential for the treatment of this disease. The paper is published in advance, online in Critical Care Medicine.

15 Nov 2013

Severe sepsis mortality rates decrease over the past 20 years

A recent study from Boston University School of Medicine and Boston Medical Center shows a significant decrease in severe sepsis mortality rates over the past 20 years. Looking at data from patients with severe sepsis enrolled in clinical trials, researchers found that in-hospital mortality rates decreased from 47 percent between 1991 and 1995 to 29 percent between 2006 and 2009, a time period when no new pharmacological treatments were developed for severe sepsis.

14 Nov 2013

Study reveals how cocaine permanently damages proteins in the body

A new study on cocaine, the notorious white powder illegally snorted, injected or smoked by nearly 2 million Americans, details how it may permanently damage proteins in the body. That information, gleaned from laboratory tests, could be used to potentially detect the drug in biofluids for weeks or months - instead of days - after use, say scientists. The findings, which appear in the ACS journal Chemical Research in Toxicology, could also help explain cocaine's long-term health effects.

14 Nov 2013

Skeletal problems now added to list of diabetes complications

The list of complications from type 2 diabetes is long: vascular and heart disease, eye problems, nerve damage, kidney disease, hearing problems and Alzheimer's disease. Physicians have long thought of osteoporosis as another outcome. Based on a Mayo Clinic study published in the Journal of Bone and Mineral Research, that's confirmed: You can definitely add skeletal problems to that list.

14 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

Stem cells from Wolfram syndrome patients used to elucidate beta-cell failure pathway in diabetes

Scientists from the New York Stem Cell Foundation Research Institute and Columbia University Medical Center have used stem cells created from the skin of patients with a rare form of diabetes—Wolfram syndrome—to elucidate an important biochemical pathway for beta-cell failure in diabetes. The findings by Linshan Shang and colleagues were published today in Diabetes.

13 Nov 2013

Tailored doses of pre-transplant drug therapy in Glaucomatous patients boosts survival rates to over 90%

Chronic Granulomatous Disease is a rare immune deficiency that seriously compromises organ function and is life-threatening, with 20-30 per cent of patients dying within the first two decades of life.

13 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Study highlights disparities in access to diabetes treatment in European countries

Hundreds of thousands of people living with diabetes in Europe do not have access to the treatment they need, putting their health at risk. These are the initial findings of a study by the International Diabetes Federation Europe on Access to Quality Medicines and Medical Devices for Diabetes Care in Europe.

13 Nov 2013

African Americans with APOL1 gene variant experience faster progression of CKD

A large study co-authored by Penn Medicine published this week in the New England Journal of Medicine found that African Americans with the APOL1 gene variant experience faster progression of chronic kidney disease and have a significantly increased risk of kidney failure, regardless of their diabetes status.

13 Nov 2013

Reflux surgery challenged for smallest children

US physicians have raised concerns over the diagnosis and treatment of gastroesophageal reflux disease in small children, especially among infants for whom regurgitation is normal and likely to resolve with conservative treatment

12 Nov 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.

12 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

Nephrology News and Research

Further Reading

Researchers generate three-dimensional kidney structures from human stem cells

Patients who undergo gastric bypass less likely to have risk of heart attack and stroke

MGH investigators identify molecule that plays key role in the breakdown of kidney filter

Satellite Healthcare, NKF partner to sponsor free Community Kidney Disease Symposium

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

Gastric bypass dramatically improves multiple cardiovascular risk factors in the long term

Small molecule compound shows significant success in controlling polyomaviruses

Annexin A5 protein may have therapeutic potential for treatment of sepsis

Severe sepsis mortality rates decrease over the past 20 years

Study reveals how cocaine permanently damages proteins in the body

Skeletal problems now added to list of diabetes complications

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Stem cells from Wolfram syndrome patients used to elucidate beta-cell failure pathway in diabetes

Tailored doses of pre-transplant drug therapy in Glaucomatous patients boosts survival rates to over 90%

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Study highlights disparities in access to diabetes treatment in European countries

African Americans with APOL1 gene variant experience faster progression of CKD

Reflux surgery challenged for smallest children

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News